Abstract
DIMSCAN is a semiautomatic fluorescence-based digital image microscopy system that quantifies relative total (using a DNA stain) or viable (using fluorescein diacetate [FDA]) cell numbers in tissue culture multiwell plates ranging from 6 to 384 wells per plate. DIMSCAN is a rapid and efficient tool for conducting in vitro cytotoxicity assays across a 4 log dynamic range. The specificity of detecting viable cells with FDA is achieved by using digital image processing and chemical quenching of fluorescence in nonviable cells with eosin Y. Average scan time for the most commonly used format, a 96-well plate, is 6 min. Cytotoxicity for neuroblastoma cell lines measured by DIMSCAN was found to be comparable to manual Trypan blue dye exclusion counts or colony formation in soft agar, but with a significantly wider dynamic range, which enables drug combination studies used to detect synergistic or antagonistic interactions. The linearity of DIMSCAN was validated (r 2 = 0.99967 ± 0.0003) for cells stained with FDA deposited using a fluorescence-activated cell sorter, documenting a dynamic range>4 logs, and the ability to detect a single viable cell in a well 93‰ of the time. DIMSCAN has been used to demonstrate preclinical activity of cytotostatic and cytotoxic drugs and drug combinations that have subsequently shown activity in clinical trials.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Pieters, R., Huismans, D. R., Leyva, A., and Veerman, A. J. (1989) Comparison of the rapid automated MTT-assay with a dye exclusion assay for chemosensitivity testing in childhood leukaemia. Br. J. Cancer 59, 217–220.
Rubinstein, L. V., Shoemaker, R. H., Paull, K. D., et al. (1990) Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst. 82, 1113–1118.
Sobottka, S. B. and Berger, M. R. (1992) Assessment of antineoplastic agents by MTT assay: partial underestimation of antiproliferative properties. Cancer Chemother. Pharmacol. 30, 385–393.
Vistica, D. T., Skehan, P., Scudiero, D., Monks, A., Pittman, A., and Boyd, M. R. (1991) Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res. 51, 2515–2520.
Gerson, S. L., Phillips, W., Kastan, M., Dumenco, L. L., and Donovan, C. (1996) Human CD34+ hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU. Blood 88, 1649–1655.
Lee, C. K., Harman, G. S., Hohl, R. J., and Gingrich, R. D. (1996) Fatal cyclophosphamide cardiomyopathy: its clinical course and treatment. Bone Marrow Transplant. 18, 573–577.
Dhar, S., Nygren, P., Csoka, K., Botling, J., Nilsson, K., and Larsson, R. (1996) Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. Br. J. Cancer 74, 888–896.
Ford, C. H., Richardson, V. J., and Tsaltas, G. (1989) Comparison of tetrazolium colorimetric and [3H]-uridine assays for in vitro chemosensitivity testing. Cancer Chemother. Pharmacol. 24, 295–301.
Skehan, P., Storeng, R., Scudiero, D., et al. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82, 1107–1112.
Leeder, J. S., Dosch, H. M., Harper, P. A., Lam, P., and Spielberg, S. P. (1989) Fluorescence-based viability assay for studies of reactive drug intermediates. Anal. Biochem. 177, 364–372.
Ross, D. D., Joneckis, C. C., Ordonez, J. V., et al. (1989) Estimation of cell survival by flow cytometric quantification of fluorescein diacetate/propidium iodide viable cell number. Cancer Res. 49, 3776–3782.
Wierda, W. G., Mehr, D. S., and Kim, Y. B. (1989) Comparison of fluorochromelabeled and 51Cr-labeled targets for natural killer cytotoxicity assay. J. Immunol. Methods 122, 15–24.
Nishio, K., Ishida, T., Arioka, H., et al. (1996) Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines. Anticancer Res. 16, 3387–3395.
Bramson, J., O’Connor, T., and Panasci, L. (1995) Effect of alkyl-N-purine DNA glycosylase overexpression on cellular resistance to bifunctional alkylating agents. Biochem. Pharmacol. 50, 39–44.
Proffitt, R. T., Tran, J. V., and Reynolds, C. P. (1996) A fluorescence digital image microscopy system for quantifying relative cell numbers in tissue culture plates. Cytometry 24, 204–213.
Wang, X. M., Terasaki, P. I., Rankin, G. W. Jr., Chia, D., Zhong, H. P., and Hardy, S. (1993) A new microcellular cytotoxicity test based on calcein AM release. Hum. Immunol. 37, 264–270.
Jensen, P. B., Holm, B., Sorensen, M., Christensen, I. J., and Sehested, M. (1997) In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. Br. J. Cancer 75, 869–877.
Reynolds, C. P. and Frgala, T. (2002) Fluorescence Digital Imaging Microscopy System (Chemical quenching of non-cellular fluorescence from fluorescein diacetate in cytotoxicity assays using eosin y and other similar vital dyes). USPTO patent no. 6,459,805.
Keshelava, N., Seeger, R. C., Groshen, S., and Reynolds, C. P. (1998) Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res. 58, 5396–5405.
O’Donnell, P. H., Guo, W. X., Reynolds, C. P., and Maurer, B. J. (2002) N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes. Leukemia 16, 902–910.
Maurer, B. J., Melton, L., Billups, C., Cabot, M. C., and Reynolds, C. P. (2000) Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J. Natl. Cancer Inst. 92, 1897–1909.
Krejsa, J., Frgala, T., Alfaro, P., and Reynolds, C. P. (2002) DIMSCAN 3.0, a new generation of flourescence digital image microscopy system for measuring cytotoxicity in microplates. Proc. Am. Assoc. Cancer Res. 43, 586.
Harrison, S. (2002) Perspective on the history of tumor models, in Tumor Models in Cancer Research (Teicher, B. A., eds.), Humana, Totowa, pp. 3–19.
Reynolds, C. P. (2000) Differentiating agents in pediatric malignancies: retinoids in neuroblastoma. Curr. Oncol. Rep. 2, 511–518.
Anderson, C. P., Seeger, R. C., Bailey, H. H., and Reynolds, C. P. (2002) Pilot of buthionine sulfoximine (BSO) combined with non-myeloablative melphalan (L-PAM) against refractory neuroblastoma (NB). Proc. Am. Soc. Clin. Oncol. 21, 298a.
Anderson, C. P. and Reynolds, C. P. (2002) Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. Bone Marrow Transplant. 30, 135–140.
Reynolds, C. P., Wang, Y., Melton, L. J., Einhorn, P. A., Slamon, D. J., and Maurer, B. J. (2000) Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide. Med. Pediatr. Oncol. 35, 597–602.
Keshelava, N., Tsao-Wei, D., and Reynolds, C. P. (2003) Pyrazoloacridine is active in multidrug-resistant neuroblastoma cell lines with nonfunctional p53. Clin. Cancer Res. 9, 3492–3502.
Chou, J. and Chou, T. C. (1987) Multiple drug-effect analysis (program B), in Dose-Effect Analysis with Microcomputers (Chou, J. and Chou, T. C., eds.), Biosoft, Cambridge, UK, pp. 19–29.
Ellwart, J. W., Kremer, J. P., and Dormer, P. (1988) Drug testing in established cell lines by flow cytometric vitality measurements versus clonogenic assay. Cancer Res. 48, 5722–5725.
Weisenthal, L. M., Marsden, J. A., Dill, P. L., and Macaluso, C. K. (1983) A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res. 43, 749–757.
Ishiyama, M., Tominaga, H., Shiga, M., Sasamoto, K., Ohkura, Y., and Ueno, K. (1996) A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol. Pharm. Bull. 19, 1518–1520.
Sevin, B. U., Peng, Z. L., Perras, J. P., Ganjei, P., Penalver, M., and Averette, H. E. (1988) Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. Gynecol. Oncol. 31, 191–204.
Metzger, R., Deglmann, C. J., Hoerrlein, S., Zapf, S., and Hilfrich, J. (2001) Towards in-vitro prediction of an in-vivo cytostatic response of human tumor cells with a fast chemosensitivity assay. Toxicology 166, 97–108.
Bosanquet, A. G. and Bell, P. B. (1996) Enhanced ex vivo drug sensitivity testing of chronic lymphocytic leukaemia using refined DiSC assay methodology. Leuk. Res. 20, 143–153.
Tanigawa, N., Kitaoka, A., Yamakawa, M., Tanisaka, K., and Kobayashi, H. (1996) In vitro chemosensitivity testing of human tumours by collagen gel droplet culture and image analysis. Anticancer Res. 16, 1925–1930.
Csoka, K., Tholander, B., Gerdin, E., de la Torre, M., Larsson, R., and Nygren, P. (1997) In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Int. J. Cancer 72, 1008–1012.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Keshelava, N., Frgala, T., Krejsa, J., Kalous, O., Patrick Reynolds, C. (2005). Dimscan. In: Blumenthal, R.D. (eds) Chemosensitivity. Methods in Molecular Medicine™, vol 110. Humana Press. https://doi.org/10.1385/1-59259-869-2:139
Download citation
DOI: https://doi.org/10.1385/1-59259-869-2:139
Publisher Name: Humana Press
Print ISBN: 978-1-58829-345-9
Online ISBN: 978-1-59259-869-4
eBook Packages: Springer Protocols